cumberland pharmaceuticals inc - CPIX
CPIX
Close Chg Chg %
6.79 -0.17 -2.50%
Pre-Market
6.62
-0.17 (2.50%)
Volume: 28.15K
Last Updated:
Sep 8, 2026, 4:00 PM EDT
Company Overview: cumberland pharmaceuticals inc - CPIX
CPIX Key Data
| Open $6.66 | Day Range 6.47 - 6.88 |
| 52 Week Range 1.85 - 9.28 | Market Cap $101.74M |
| Shares Outstanding 14.98M | Public Float 8.75M |
| Beta 0.10 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.73 |
| Yield 0.00% | Dividend $1.50 |
| EX-DIVIDEND DATE Aug 3, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 73.29K |
CPIX Performance
| 1 Week | 0.00% | ||
| 1 Month | -12.95% | ||
| 3 Months | 21.25% | ||
| 1 Year | 97.38% | ||
| 5 Years | 143.37% |
CPIX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About cumberland pharmaceuticals inc - CPIX
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
CPIX At a Glance
Cumberland Pharmaceuticals, Inc.
1600 West End Avenue
Nashville, Tennessee 37203
| Phone | 1-615-255-0068 | Revenue | 44.52M | |
| Industry | Pharmaceuticals: Major | Net Income | -2,836,128.00 | |
| Sector | Health Technology | 2025 Sales Growth | 17.57% | |
| Fiscal Year-end | 12 / 2026 | Employees | 93 | |
| View SEC Filings |
CPIX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.328 |
| Price to Book Ratio | 2.393 |
| Price to Cash Flow Ratio | 11.99 |
| Enterprise Value to EBITDA | 22.122 |
| Enterprise Value to Sales | 1.292 |
| Total Debt to Enterprise Value | 0.177 |
CPIX Efficiency
| Revenue/Employee | 478,725.065 |
| Income Per Employee | -30,496.00 |
| Receivables Turnover | 2.627 |
| Total Asset Turnover | 0.584 |
CPIX Liquidity
| Current Ratio | 1.009 |
| Quick Ratio | 0.839 |
| Cash Ratio | 0.311 |
CPIX Profitability
| Gross Margin | 75.714 |
| Operating Margin | -6.033 |
| Pretax Margin | -6.314 |
| Net Margin | -6.37 |
| Return on Assets | -3.722 |
| Return on Equity | -11.883 |
| Return on Total Capital | -8.089 |
| Return on Invested Capital | -7.817 |
CPIX Capital Structure
| Total Debt to Total Equity | 40.918 |
| Total Debt to Total Capital | 29.037 |
| Total Debt to Total Assets | 13.252 |
| Long-Term Debt to Equity | 39.038 |
| Long-Term Debt to Total Capital | 27.702 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Cumberland Pharmaceuticals Inc - CPIX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 42.01M | 39.55M | 37.87M | 44.52M | |
Sales Growth
| +16.75% | -5.85% | -4.26% | +17.57% | |
Cost of Goods Sold (COGS) incl D&A
| 14.45M | 11.00M | 11.49M | 10.81M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 5.33M | 5.77M | 6.04M | 5.29M | |
Depreciation
| 260.75K | 1.01M | 1.30M | 1.25M | |
Amortization of Intangibles
| 5.07M | 4.76M | 4.75M | 4.03M | |
COGS Growth
| +7.67% | -23.84% | +4.42% | -5.89% | |
Gross Income
| 27.56M | 28.55M | 26.38M | 33.71M | |
Gross Income Growth
| +22.14% | +3.58% | -7.60% | +27.79% | |
Gross Profit Margin
| +65.61% | +72.18% | +69.66% | +75.71% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 33.27M | 35.03M | 33.48M | 36.39M | |
Research & Development
| 6.69M | 5.83M | 4.82M | 5.57M | |
Other SG&A
| 26.58M | 29.20M | 28.66M | 30.83M | |
SGA Growth
| +5.98% | +5.30% | -4.43% | +8.70% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 2.25M | (906.07K) | 106.22K | |
EBIT after Unusual Expense
| (5.70M) | (8.73M) | (6.20M) | (2.79M) | |
Non Operating Income/Expense
| 709.74K | 3.12M | 334.44K | 476.75K | |
Non-Operating Interest Income
| 98.41K | 286.85K | 334.44K | 476.75K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 586.00K | 667.86K | 605.51K | 495.99K | |
Interest Expense Growth
| +497.76% | +13.97% | -9.34% | -18.09% | |
Gross Interest Expense
| 586.00K | 667.86K | 605.51K | 495.99K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (5.58M) | (6.28M) | (6.47M) | (2.81M) | |
Pretax Income Growth
| -0.34% | -12.61% | -2.89% | +56.53% | |
Pretax Margin
| -13.29% | -15.89% | -17.08% | -6.31% | |
Income Tax
| 68.85K | 45.77K | (22.67K) | 40.26K | |
Income Tax - Current - Domestic
| - | - | (22.67K) | 40.26K | - |
Income Tax - Current - Foreign
| - | - | 68.85K | 45.77K | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (5.65M) | (6.33M) | (6.44M) | (2.86M) | |
Minority Interest Expense
| (79.80K) | (51.45K) | 36.05K | (28.58K) | |
Net Income
| (5.57M) | (6.28M) | (6.48M) | (2.84M) | |
Net Income Growth
| -1.24% | -12.73% | -3.19% | +56.23% | |
Net Margin Growth
| -13.26% | -15.88% | -17.11% | -6.37% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (5.57M) | (6.28M) | (6.48M) | (2.84M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (5.57M) | (6.28M) | (6.48M) | (2.84M) | |
EPS (Basic)
| -0.3825 | -0.4392 | -0.4609 | -0.1909 | |
EPS (Basic) Growth
| -62.56% | -14.82% | -4.94% | +58.58% | |
Basic Shares Outstanding
| 14.56M | 14.30M | 14.06M | 14.85M | |
EPS (Diluted)
| -0.3825 | -0.4392 | -0.4609 | -0.1909 | |
EPS (Diluted) Growth
| -62.56% | -14.82% | -4.94% | +58.58% | |
Diluted Shares Outstanding
| 14.56M | 14.30M | 14.06M | 14.85M | |
EBITDA
| (376.82K) | (710.85K) | (1.06M) | 2.60M | |
EBITDA Growth
| +91.07% | -88.64% | -48.85% | +345.74% | |
EBITDA Margin
| -0.90% | -1.80% | -2.79% | +5.84% |
An error occurred while fetching the data.
SEC Filings for Cumberland Pharmaceuticals Inc - CPIX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cumberland Pharmaceuticals Inc - CPIX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,427 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.37 per share | 19,210,438.99 |
| Nov 3, 2025 | Caroline R. Young Director | 33,168 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.39 per share | 112,439.52 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,544 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.28 per share | 18,697,784.32 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,531 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.49 per share | 19,894,853.19 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,518 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.51 per share | 20,008,818.18 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,505 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.44 per share | 19,609,737.20 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,492 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.62 per share | 20,635,781.04 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,479 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.61 per share | 20,578,729.19 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,466 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.52 per share | 20,065,640.32 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,453 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.48 per share | 19,837,576.44 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,440 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.49 per share | 19,894,535.60 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,297 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.31 per share | 18,867,983.07 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,414 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.35 per share | 19,096,386.90 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,401 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.54 per share | 20,179,419.54 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,388 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.59 per share | 20,464,392.92 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,375 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.56 per share | 20,293,335.00 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,362 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.63 per share | 20,692,314.06 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,349 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.19 per share | 18,184,113.31 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,336 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.14 per share | 17,899,055.04 |
| Nov 3, 2025 | A. J. Kazimi Chairman and CEO; Director | 5,700,323 | Small acquisition under Rule 16a-6 Non-derivative transaction at $3.25 per share | 18,526,049.75 |